Amarin posts Q2 2026 results as international partner sales grow, US expenses fall

Amarin Corporation plc reported financial results for the second quarter ended June 30, 2026 on July 29, 2026, marking roughly one year since it shifted to a fully partnered international commercial model. In June 2025, Amarin signed a long-term license and supply agreement giving Recordati S.p.A. rights to commercialize VASCEPA/VAZKEPA in 59 countries focused on Europe.¹

Amarin said in-market demand increased 59% year over year across its global partner network in Q2 2026¹, and in-market volume in China grew 90% year to date versus the same period last year.¹ In-market demand in Europe for VAZKEPA rose 69% in Q2 2026 from Q2 2025.¹ As of June 30, 2026, VASCEPA/VAZKEPA was commercially available in 22 countries globally, including 11 countries in Europe under the Recordati license.¹ The company noted continued progress across Europe and Asia, saying Singapore and South Korea are moving toward commercialization in the near term.¹

In the U.S., Amarin's share of the IPE market rose to 48% in Q2 2026 from 43% a year earlier, with VASCEPA branded prescriptions up 14%.¹ The company said it expects U.S. volumes to stay consistent through the rest of 2026.¹

On expenses, operating expenses excluding restructuring charges fell $16.6 million, or 38%, compared to Q2 2025, consistent with a previously announced $70 million annual cost savings plan that the company said is now complete.¹

On cash, Amarin reported $314.6 million in cash as of June 30, 2026, up from $302.6 million at December 31, 2025.¹ The company said it expects cash to grow about 10% by December 31, 2026 compared to year-end 2025.¹ Amarin said it remained debt free as of June 30, 2026.¹ CFO Peter Fishman said the company generated positive cash flow for a third consecutive quarter.¹